Pacira BioSciences (PCRX) Proxy filing summary

Executive summary

• Stockholders are urged to vote for three highly qualified director nominees to maintain strategic momentum and long-term value creation.

• The 5x30 strategy has delivered record financial results, including highest-ever total revenue and gross margins in 2025, and strong year-over-year growth in key products in Q1 2026.

• Independent proxy advisors ISS, Glass Lewis, and Egan-Jones recommend voting for the board's nominees and against DOMA's nominees.

• Forward-looking statements highlight ongoing product development, market expansion, and risk factors affecting future performance.

Voting matters and shareholder proposals

• Stockholders are asked to vote for three board nominees on the BLUE proxy card and against all DOMA Perpetual Capital Management LLC nominees.

• Proxy advisors support the board's nominees, citing their expertise and alignment with shareholder interests.

• DOMA's campaign is criticized for lacking a credible plan and proposing underqualified nominees.

Board of directors and corporate governance

• The board is described as purpose-built with expertise in biopharmaceutical development, commercialization, public policy, and operations.

• Nominees have public company board experience and a track record in overseeing mergers and acquisitions.